Neo Ivy Capital Management Makes New Investment in Charles River Laboratories International, Inc. (NYSE:CRL)

Neo Ivy Capital Management acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 4,902 shares of the medical research company's stock, valued at approximately $966,000.

Several other hedge funds have also recently made changes to their positions in the stock. Oregon Public Employees Retirement Fund raised its holdings in shares of Charles River Laboratories International by 1.0% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company's stock worth $914,000 after acquiring an additional 45 shares in the last quarter. Empirical Finance LLC grew its stake in Charles River Laboratories International by 4.2% in the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company's stock worth $258,000 after purchasing an additional 53 shares in the last quarter. American Trust increased its holdings in Charles River Laboratories International by 5.9% during the 2nd quarter. American Trust now owns 976 shares of the medical research company's stock worth $202,000 after purchasing an additional 54 shares during the period. Tortoise Investment Management LLC raised its position in Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock valued at $27,000 after purchasing an additional 57 shares in the last quarter. Finally, OLD National Bancorp IN lifted its stake in Charles River Laboratories International by 3.1% in the third quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company's stock worth $392,000 after acquiring an additional 59 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. StockNews.com cut Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Thursday, November 7th. TD Cowen raised their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a research note on Monday, November 11th. CLSA downgraded shares of Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price objective on the stock. in a report on Monday, November 18th. Evercore ISI raised their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an "in-line" rating in a report on Thursday, November 7th. Finally, Robert W. Baird lowered their price target on shares of Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating on the stock in a report on Friday, September 20th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $214.38.

Charles River Laboratories International Price Performance

NYSE CRL traded up $0.84 on Thursday, hitting $194.39. The company had a trading volume of 520,520 shares, compared to its average volume of 616,945. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The company's fifty day moving average price is $194.36 and its 200-day moving average price is $203.28. The company has a market capitalization of $9.94 billion, a PE ratio of 24.33, a PEG ratio of 4.95 and a beta of 1.38. Charles River Laboratories International, Inc. has a 12-month low of $176.48 and a 12-month high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. During the same quarter last year, the business earned $2.72 earnings per share. The company's revenue for the quarter was down 1.6% compared to the same quarter last year. As a group, analysts predict that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

Insider Activity

In other news, Director Richard F. Wallman sold 6,621 shares of the firm's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares of the company's stock, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 1.30% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).